FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150541210> ?p ?o ?g. }

• W2150541210 endingPage "2652" @default.
• W2150541210 startingPage "2646" @default.
• W2150541210 abstract "HomeCirculationVol. 107, No. 21Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBClinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils Alexander Leaf, MD, Jing X. Kang, MD, PhD, Yong-Fu Xiao, MD, PhD and George E. Billman, PhD Alexander LeafAlexander Leaf From the Departments of Medicine, Massachusetts General Hospital (A.L., J.X.K., Y.-F.X.) and the Beth Israel Deaconess Medical Center (Y.-F.X.), Harvard Medical School, Boston, Mass, and the Department of Physiology and Cell Biology (G.E.B.), Ohio State University, Columbus, Ohio. Search for more papers by this author , Jing X. KangJing X. Kang From the Departments of Medicine, Massachusetts General Hospital (A.L., J.X.K., Y.-F.X.) and the Beth Israel Deaconess Medical Center (Y.-F.X.), Harvard Medical School, Boston, Mass, and the Department of Physiology and Cell Biology (G.E.B.), Ohio State University, Columbus, Ohio. Search for more papers by this author , Yong-Fu XiaoYong-Fu Xiao From the Departments of Medicine, Massachusetts General Hospital (A.L., J.X.K., Y.-F.X.) and the Beth Israel Deaconess Medical Center (Y.-F.X.), Harvard Medical School, Boston, Mass, and the Department of Physiology and Cell Biology (G.E.B.), Ohio State University, Columbus, Ohio. Search for more papers by this author and George E. BillmanGeorge E. Billman From the Departments of Medicine, Massachusetts General Hospital (A.L., J.X.K., Y.-F.X.) and the Beth Israel Deaconess Medical Center (Y.-F.X.), Harvard Medical School, Boston, Mass, and the Department of Physiology and Cell Biology (G.E.B.), Ohio State University, Columbus, Ohio. Search for more papers by this author Originally published3 Jun 2003https://doi.org/10.1161/01.CIR.0000069566.78305.33Circulation. 2003;107:2646–2652This review will be limited specifically to the beneficial prevention by the n-3 polyunsaturated fatty acids (PUFAs) of arrhythmic deaths, including sudden cardiac death, which annually causes some 300 000 deaths in the United States and millions more worldwide. We will also show that the growing body of positive clinical studies is supported by what has been learned in animal and laboratory studies regarding the mechanism by which n-3 PUFAs prevent cardiac arrhythmias.See p 2632The Essential PUFAsFigure 1 shows the 2 essential classes of PUFAs, the n-6 (ω6) and n-3 (ω3) classes. Both classes are “essential” because we cannot make them in our bodies. They must come in our diets, and they are essential for normal growth, development, and optimal function of brain, heart, and probably other systems. The parent fatty acid of the n-6 class, linoleic acid (C18:2n-6; LA) has 18 carbon atoms in its acyl chain, and the first C=C double bond is 6 carbons back from the methyl end of the fatty acid, hence the “n-6” appellation. In the bodies of animals, including humans, LA can be elongated and desaturated through a series of enzymatic steps to form arachidonic acid (C20:4n-6; AA). AA is the source of the n-6 eicosanoids that result from oxygenation of AA by cyclooxygenase, lipoxygenase, and epoxygenase enzymes to form prostaglandins, leukotrienes, lipoxines, and P-450 compounds, which in many instances are potent cell messengers. Download figureDownload PowerPointFigure 1. Two classes of essential PUFAs.In the chloroplast of green plants, algae, and phytoplankton, LA can be further desaturated in the n-3 position to yield α-linolenic acid (C18:3 n-3; ALA), the 18-carbon parent fatty acid of the n-3 class. ALA can be further elongated and desaturated by the same enzymes that convert n-6 LA to AA to form the 20-carbon n-3 analog of AA, namely, eicosapentaenoic acid (C20:5n-3; EPA). EPA in turn can compete with AA for the same cyclooxygenase, lipoxygenase, and epoxygenase enzymes to form a different class of eicosanoids, which in several important instances can oppose and counteract the action of the n-6 eicosanoids.1 The final elongation desaturation product of the n-3 class is docosahexaenoic acid (C22:6n-3; DHA), the longest and most unsaturated fatty acid normally encountered in our diets. EPA and DHA are physiologically the most important members of the n-3 class. Their source is largely from marine vertebrates, and they are accumulated in the phospholipids in our cell membranes, especially in brain, heart, and testes.Clinical n-3 Fatty Acid StudiesThe first clinical cardiovascular trial was reported in 1989 by Burr and associates.2 They performed a randomized controlled trial with a factorial design in 2033 men to determine whether dietary advice on fat, fish, or fiber is beneficial in the secondary prevention of myocardial infarction (MI). No benefits accrued from the fat and fiber advice. At the end of 2 years, however, there was a 29% reduction in mortality in the 1015 men who had received advice to eat oily fish, at least 200- to 400-g portions twice weekly, compared with the 1018 men who had not received such advice. There were no significant differences in ischemic heart disease events between the 2 groups because more nonfatal infarcts occurred in the group that was advised to eat fish. The mortality difference in favor of fish advice appeared early and persisted up to 2 years. Over the 2 years, there were no significant differences in levels of total cholesterol. This study was published before the antiarrhythmic effects of fish oils were generally known, but the reduced mortality in those advised to eat fish despite an increase in MIs in this cohort suggests that the findings resulted from a reduction in arrhythmic deaths. Fifty percent to 60% of deaths in the setting of coronary heart disease are sudden cardiac death (deaths within 1 hour of symptoms of an acute MI) attributed to sustained ventricular arrhythmias.3 Patients were still experiencing MIs but were not dying as frequently from them. The cardiology and medical communities paid little attention to this Diet and Reinfarction Trial (DART), coming as it did seemingly out of the blue.The second noteworthy trial was published in 1994.4 It was a prospective secondary, single-blinded prevention trial comparing the effect of a Mediterranean ALA-rich diet (n=302) to the usual postinfarction prudent diet (n=303). The experimental group consumed significantly less lipids, saturated fat, cholesterol, and linoleic acid but more oleic acids and ALAs, which was confirmed by measurements in plasma. The study was expected to last for 5 years, but after a mean follow-up of 27 months, the study was terminated by its Science and Ethics Review Committee because the results were so beneficial. There were already 16 cardiac deaths in the control group and 3 in the experimental group (of the 16 deaths in the control group, 8 resulted from sudden cardiac death, whereas there were no such deaths in the experimental group). Seventeen nonfatal MIs occurred in the control group and 5 in the experimental group, giving a combined risk ratio of 0.27 (P=0.001). Overall mortality was 20 in the control and 8 in the experimental group. Such clinical cardiac benefits have not been achieved before or since from solely a dietary study, and the trial requires confirmation. Benefits cannot be ascribed to the n-3 fatty acids specifically, although higher concentrations of n-3 fatty acids in plasma were documented in the experimental group. There were, however, considerable other dietary differences in intake of fresh fruits, vegetables, legumes, and grains. The benefits of the experimental diet appeared early and persisted for the full 2 years. There were no changes in blood cholesterol or in any component of the blood lipids. Despite termination of the study at 27 months and the requirement that each subject in the control group be informed personally of the reason that the study had been terminated, de Lorgeril and associates continued to follow both groups to 46 months’ follow-up and published their findings.5 Surprisingly, the 70% mortality difference favoring the experimental group persisted. This speaks volumes for the palatability of the experimental diet and the need for doctors, nurses, and dietitians to thoroughly indoctrinate patients with regard to a diet if they are to have any expectation for good adherence.In 1999, another notable clinical trial was reported, the GISSI-Prevenzione trial.6 This was a large, prospective, randomized, clinical trial of 11 324 patients who had a recent MI. They were randomly assigned to 4 equal groups to test the effects of a daily dose of 1 capsule of 850 mg of EPA plus DHA, 300 mg of vitamin E, n-3 PUFA plus vitamin E, and a control group that received neither fatty acids nor vitamin E. This supplementation was in addition to optimal pharmacological treatment and lifestyle advice. The primary combined efficacy end point was death, nonfatal MI, and stroke. At 3.5 years, there were no significant benefits resulting from the vitamin E supplement. The n-3 PUFA supplement significantly reduced the primary end point by 10% (2-way analysis) and 15% (4-way analysis). Treatment lowered the relative risk of death by 14% or 20% (2-way or 4-way analysis, respectively) and lowered the risk of cardiovascular death by 17% or 30%. Although not a stated primary end point, there was a 45% reduction in sudden cardiac death (4-way analysis).This study was reanalyzed and subsequently published again in 2002.7 This reanalysis showed the reduction in risk of sudden cardiac death was nearly significant at 3 months, accounting for 67% of the overall mortality benefit, became significant at 4 months, and was highly significant at 3.5 years, the end of the study, when it accounted for 59% of the n-3 PUFA advantage in mortality. In fact, the reduction observed in all-cause mortality and in cardiovascular mortality resulted mainly from the prevention of sudden cardiac death by the n-3 fatty acids. As in the previous 2 reports, the benefit occurred early and resulted despite the lack of a change in the blood lipids. Also, as in the DART study, no reduction in nonfatal MIs occurred.Another prospective randomized trial was reported by Singh et al.8 Patients presenting with suspected MI (n= 360) were randomized to placebo, fish oil (2 g of EPA plus DHA daily), or mustard seed oil (containing 2.9 g of ALA per day). In 1 year, there were fewer cardiac deaths, including sudden death, in the fish oil group than in the placebo cohort (11.2% versus 22.0%, P<0.05). A case-control study9 reported an inverse relationship between fish consumption and out-of-hospital sudden cardiac death, which suggests an antiarrhythmic effect from ingestion of fish. A review of the Physicians’ Health Study reported that those who ingested at least 2 fish meals per week had a 52% lower risk of sudden cardiac death.10More recently, the data in the Physicians’ Health Study have been examined to test whether n-3 fatty acid consumption would reduce the risk of sudden death in subjects without a history of preexisting cardiovascular disease. A prospective, nested, case-control analysis among apparently healthy men who were followed up for 17 years in the Physicians’ Health Study was conducted retrospectively.11 Ninety-four men were identified in whom sudden cardiac death occurred as the first manifestation of cardiovascular disease. The fatty acid composition of blood, which had been collected at baseline on all subjects, was determined. Baseline blood levels of long-chain n-3 fatty acids were very significantly inversely related to the risk of sudden death. Compared with the men whose blood levels of the n-3 fish oil fatty acids were in the lowest quartile, the relative risk of sudden death was significantly lower among men in the third quartile (relative risk ratio, 0.28) and in the fourth quartile (0.19). The 72% and 81% relative risk reductions are the largest beneficial cardiac effects of the n-3 PUFAs reported thus far in humans.The evidence has been strengthened that fish oil fatty acids can prevent sudden cardiac death in humans, and this may prove to be their major cardiac benefit. Indeed, in the DART and the GISSI-Prevenzione studies cited above, there were no reductions in nonfatal MIs.Animal and Laboratory StudiesIn the mid-1970s, Gudbjarnason and Hallgrimsson12 suggested that fish oils might be antiarrhythmic. Later, Murnaghan13 reported that ALA administered to a rabbit heart in a Langendorff preparation increased the arrhythmia threshold of the heart. Two Australian investigators, Peter McLennan and John Charnock, began to study possible antiarrhythmic effects of the fish oil fatty acids.14 Their basic experiment was direct and simple. They fed rats diets in which they could control the major fat component for 3 or more months. At the end of the dietary period, they ligated the coronary arteries of the rats and counted the number of animals that died of sustained ventricular fibrillation (VF). In one report,15 McLennan showed that slightly more than 40% of the animals fed a diet with saturated fat providing 12% of energy calories died of sustained VF. This was not significantly reduced by an olive oil (monounsaturated fat) diet, whereas the group receiving tuna fish oil (rich in n-3 PUFAs) had no arrhythmic deaths. These investigators also reported a similar antiarrhythmic action of the n-3 PUFAs in nonhuman primates.16 Since then, others have repeated their findings in rats.17–20 When we learned about their findings, we decided that we should at least try to confirm their surprising results.This was done with a highly reliable dog model of sudden cardiac death.21 A surgically induced anterior MI was produced, and a hydraulic, inflatable cuff was left around the left circumflex coronary artery so it could be compressed at will. The dogs were then trained to run on a treadmill during the month allowed for recovery from the surgery and the anterior MI. The result of the exercise stress combined with an additional ischemic insult to the heart when the left circumflex artery was occluded caused some 60% of the dogs to go into a fatal VF within 2 minutes of the compression of the circumflex coronary artery. These responsive dogs provided a stable preparation in which to test potential antiarrhythmic agents and are the ones we studied.Figure 2 illustrates the typical response of one of the susceptible dogs to the exercise-ischemia protocol.22 The top control No. 1 tracing is an electroventriculogram. Because the dog was running on the treadmill, its pulse rate is elevated. The additional ischemic stress from occlusion of the left circumflex coronary artery for 2 minutes resulted in a ventricular flutter, and the circulation failed. As soon as the dog lost consciousness, it was defibrillated. The second tracing is of the same dog brought back into the laboratory 1 week later, when the same protocol was repeated. This time, just before the left circumflex coronary artery was occluded, an emulsion of free n-3 fatty acids was administered intravenously. Additional ischemic stress from occluding the left circumflex coronary artery this time failed to induce VF. One week later, control No. 2 was performed on the same dog, and an emulsion of soybean oil, which lacks any free n-3 fatty acids, was infused. Within 2 minutes of occluding the left circumflex artery, VF occurred. This is the protocol we used to test the antiarrhythmic action of the n-3 fish oil fatty acids with a control 1 week before and 1 week after the test with the infusion intravenously of the fish oil free fatty acids.22–24 The Table summarizes our experiments on the dogs. Download figureDownload PowerPointFigure 2. Representative ventricular electrogram from same dog with and without intravenous treatment with n-3 fatty acids.22 Control 1: exercise-plus-ischemia test 1 week before n-3 fatty acid exercise-plus-ischemia test. Control 2 repeated after infusion of lipid emulsion derived from soybean oil (Intralipid) lacking free long-chain n-3 EPA or DHA. Second control was performed 1 week after n-3 fatty acid exercise-plus-ischemia test.Prevention of Ischemia-Induced Fatal Ventricular Arrhythmias by n-3 Polyunsaturated Fatty Acids in a Dog Model of Sudden Cardiac Deathn-3 PUFAsNo. of Dogs TestedPTotalProtected*72% n-3 PUFA with free EPA 33.9% and DHA 25%.†98.4% free EPA; 1.1% free DHA.‡90.8% free DHA; 0.9% free EPA.§>99% free ALA.Fish oil concentrate*1310<0.005EPA†75<0.02DHA‡86<0.004α-LNA§86<0.004The prevention of fatal arrhythmias by the emulsion of fish oil concentrate (P<0.005) confirms the studies of McLennan et al.14–16 They used long feeding experiments, which were criticized because of possible confounding factors occurring in long-term dietary studies in animals. We intravenously infused free fatty acids just before an ischemic stress in our prepared dogs. We believed that if the n-3 fatty acid infusion were promptly associated with an effect in the protocol we used, we could feel confident that the effect resulted from what had just been infused.Because fish oil contains many ingredients, we wanted to know which ingredients were effective. When we tested pure EPA and DHA, each alone carried on serum albumin was highly protective.24 Even the parent fatty acid of the n-3 class of PUFAs, ALA, which is not generally present in fish oil, was protective.24 We were unable to test sufficient dogs to learn whether one fatty acid was more potent than the other.n-3 PUFAs and Cultured Neonatal Rat CardiomyocytesTo learn whether there were any plausible biochemical or physiological effects of these n-3 fatty acids that could explain their antiarrhythmic action, the effects of the n-3 PUFAs on cultured neonatal cardiomyocytes were studied. One can quickly remove the hearts from several 1- to 2-day-old rat pups and separate the individual myocytes enzymatically. The myocytes are then plated on microscope coverslips and grown in appropriate culture medium. By the second day in culture, the heart cells are adherent in monolayer clumps to the coverslip, and each clump is beating spontaneously, rhythmically, and simultaneously. A coverslip with cells is transferred to a temperature-controlled perfusion chamber on an inverted microscope. With a video camera, a monitor screen, and an edge monitor, one can focus on the contraction of a single myocyte in a clump of myocytes and preserve a tracing of the contraction amplitude and rate of contractions with a recorder.Figure 3 shows the characteristic slowing of the beating rate of the myocytes when low micromolar concentrations of EPA or DHA were added to the medium bathing the isolated heart cells. This effect was reversible. When delipidated bovine serum albumin (BSA) was added to the superfusate, the EPA or DHA was extracted from the heart cells, and the beating rate returned to the control rates.25 Toxic agents known to produce fatal arrhythmias in humans were added to the medium bathing the cultured cells, and the effects of adding the n-3 fatty acids were observed. We tested increased extracellular Ca2+,25 the cardiac glycoside ouabain,25 isoproterenol,26 lysophosphatidylcholine and acylcarnitine,27 thromboxane,28 and even the Ca2+ ionophore A23187.27 All of these agents induced tachyarrhythmias in the isolated myocytes. Download figureDownload PowerPointFigure 3. Effects of EPA and DHA on contractions of isolated neonatal rat cardiomyocytes.25 Perfusion of myocytes with 5 μmol/L EPA (A) or 5 μmol/L DHA (B) reduced beating rate by 50% within 2 minutes. Addition of delipidated BSA to perfusate extracted EPA or DHA and returned contraction rate to control level. Tracing C shows similar effect of lidocaine (20 μmol/L) on contractions of cardiomyocytes.Figure 4 shows the effects of elevated perfusate Ca2+ and ouabain on the myoctes.25 Both agents induced rapid contractions, contractures, and fibrillation of the myocytes. When EPA was added to the superfusate, the beating rate slowed, and when the high Ca2+ or ouabain was added in the presence of the EPA, no arrhythmia was induced. Furthermore, as shown in Figure 4C, after a violent fibrillation was induced in the cells by both elevated calcium and ouabain, addition of EPA stopped the arrhythmias, and the cells resumed their fairly regular contractions. The addition of the delipidated BSA to remove the free fatty acid from the myocytes resulted in recurrence of the arrhythmia. This taught us 2 important facts. First, the EPA could be extracted from the cells in the continued presence of the toxins, and the arrhythmia would return, which indicated that the fatty acids were acting without strong ionic or covalent binding to any constituent in the cell membrane. If they had such binding, we would not have been able to extract the EPA from the cells with the albumin. It appears the free fatty acids act directly on the heart cells and need only partition (dissolve) into the hospitable hydrophobic interior of phospholipids of the plasma membranes of myocytes to elicit their antiarrhythmic actions. Second, when we tested the ethyl ester of the EPA, it had no prompt antiarrhythmic action; only the free fatty acid with its negative carboxyl charge was antiarrhythmic. Download figureDownload PowerPointFigure 4. Prevention and termination of arrhythmias by EPA.25 Perfusion of myocytes with medium containing 7 mmol/L Ca2+ (A, a) or 0.1 mmol/L ouabain (B, a) induced contracture and fibrillation of myocytes. Washing cells with medium containing Ca2+ 1.2 mmol/L returned fibrillations to original beating rate (not shown). Myocytes were then perfused with medium containing 7 μmol/L EPA. When beating rate had slowed (5 to 8 bpm), addition of 7 mmol/L Ca2+ (A, b) or 0.1 mmol/L ouabain (B, b) failed to induce contractures or fibrillations. Slow beating rates were returned to original rates by perfusion with albumin (not shown). C, Fibrillation was induced by ouabain (0.1 mmol/L) plus Ca2+ (5 mmol/L) in perfusing medium. Addition of EPA (8 μmol/L) terminated fibrillation. Subsequent addition of delipidated BSA 2 mg/mL, still in presence of ouabain and high Ca2+ concentrations, extracted free EPA, and fibrillation resumed.At this point, we had found that the arrhythmias induced in the isolated neonatal rat cardiomyocytes could be prevented in every instance by the prior addition of EPA or DHA to the superfusate bathing the cells. Addition of EPA or DHA after an arrhythmia was induced would stop the arrhythmia. It was apparent that the n-3 PUFAs were affecting the excitability/automaticity of the cardiomyocytes, so the effects of the n-3 PUFAs on the electrophysiology of the myocytes were examined.29Heart, brain, and muscle are excitable tissues, and their function is to generate electrical currents to signal their actions in the body. They do this by activating and then inactivating ion channels in their plasma membranes to allow specific ions to move through their plasma membranes, thus creating ionic currents. In heart cells, these ionic currents create action potentials by the sequential opening and closing of fast voltage-dependent sodium currents into the cardiomyocytes (Figure 5). The fast movement of positive Na+ ions into the myocyte depolarizes the resting membrane potential and initiates an action potential. This is followed by outwardly directed potassium currents (Ito, the initial outward current, and Ik, the delayed rectifier current), which move positive K+ ions out of the cells repolarizing the myocytes back to their resting membrane potential. An inward calcium current, ICa,L temporarily delays repolarization of the membrane potential by bringing positive Ca2+ into the myocytes producing the plateau of the action potential. The orderly occurrence of these currents creates the action potentials, which couple the electrical and mechanical functions of the heart, resulting in its rhythmic contractions. Fatal arrhythmias occur when the electrical signals become chaotic and the heart can no longer function as a pump. Download figureDownload PowerPointFigure 5. Schematic depiction of normal cardiac action potential, as described in text.The n-3 fatty acids modulate the ionic currents in the plasma membrane of heart cells30 and the human myocardial sodium channel expressed in HEK293 cells.31,32 There is an effect of n-3 PUFAs on the sodium current, which contributes significantly to their antiarrhythmic action. These fatty acids shift the steady state inactivation to hyperpolarized potentials30–32 (Figure 6). When an ion channel opens, it is considered to be in its activated state. The subsequent closing of the ion channel occurs during its inactivated state. After an action potential, repolarization of the normal myocyte resting potential occurs promptly but before most sodium channels have recovered to their closed state, from which they can respond again with an action potential to another depolarizing stimulus. They are still relatively refractory, but that refractory period can be markedly prolonged by the presence of the n-3 fatty acids,31,32 which shift the steady state inactivation to hyperpolarized potentials. This simply means that in the presence of the n-3 PUFA, a considerably longer time or a more negative membrane potential is required to return the sodium channels to their resting, closed, but activatable state. Download figureDownload PowerPointFigure 6. Effects of EPA on activation and inactivation of human myocardial sodium channel (α- plus β-subunits) expressed in HEK293t cells.35 A, Normalized current-voltage relationships in absence (control) and presence of 5 μmol/L EPA (n=8). B, Relative whole-cell activation conductance in absence and presence of 5 μmol/L EPA. Normalized activation curves are superimposable, which indicates that EPA has no effect on activation of sodium current. C, Effects of EPA on normalized steady state inactivation of sodium current (n=7) in presence and absence of 5 μmol/L EPA and after washout. Shift to left at V1/2 = −12 mV. This shift of steady state inactivation to more hyperpolarized potentials is an important feature of action of n-3 fish oil fatty acids in preventing arrhythmias.Our Current HypothesisOur current hypothesis regarding the mechanism of action of the n-3 PUFAs to prevent fatal arrhythmias is based on their actions to inhibit the fast, voltage-dependent sodium current30–32 and the L-type calcium currents.33 With an MI, a gradient of depolarization of cardiomyocytes occurs. In the central core of the ischemic zone, cells rapidly depolarize and die. The depolarization results from deficiency of ATP in the ischemic cells, which causes a dysfunctional Na,K-ATPase and the rise of interstitial K+ concentrations in the ischemic zone. However, at the periphery of the ischemic zone, myocytes may be only partially depolarized. They become hyperexcitable because their resting membrane has become more positive, approaching the threshold for generating action potentials (activating fast Na+ channels). Thus, any additional small depolarizing stimulus (eg, current of injury) may elicit an action potential, which, if it occurs at a vulnerable moment during the cardiac electrical cycle, may initiate an arrhythmia. With nonhomogeneous rates of conduction pathways in the ischemic tissue, reentry arrhythmias are likely. In the presence of the n-3 PUFAs, however, a voltage-dependent shift of the steady state inactivation curve to more hyperpolarized potentials occurs. The consequence of this hyperpolarizing shift is that sodium channel availability is decreased, and the potential necessary to return these Na+ channels in partially depolarized myocytes to a closed but activatable state is physiologically unobtainable. Also, these partially depolarized cells have Na+ channels, which in milliseconds can slip into “resting inactivation” in response to subthreshold depolarizations without eliciting an action potential,34,35 and they do this even faster in the presence of the fish oil fatty acids.31,32 The results of these effects of the n-3 PUFAs is that these partially depolarized myocytes are quickly made inexcitable, and their potential arrhythmic mischief is aborted. Myocytes with normal membrane potentials in the nonischemic myocardium will not be so drastically affected by the PUFAs and will continue to function normally. In our opinion, this effect of the n-3 PUFAs on Na+ channels and their effect to inhibit L-type Ca2+ channels33 and prevent triggered arrhythmic afterpotential discharges caused by excessive cytosolic Ca2+ fluctuations are the major mechanisms for the antiarrhythmic effects of these PUFAs.This electrical stabilizing action of the n-3 fatty acids can be demonstrated by a simple experiment. Figure 7 shows a continuous tracing of the contraction of a single myocyte in a clump of myocytes on a microscope coverslip.27 Initially, the myocyte is contracting regularly. Two platinum electrodes were placed across the coverslip, with their tips dipped into the fluid perfusing the heart cells, and connected to a voltage source. At 15 V, it was possible to double or triple the spontaneous beating rate. When the external voltage source was turned off, the cell resumed its control spontaneous beating rate. The next line is a continuation of the recording from the same cell. When EPA was added to the superfusate, the beating rate began to slow, and now the myocyte paid no attention to stimuli at 15 V or at 20 V from the external source. At 25 V, the cell responded, but only to every other stimulus. When delipidated BSA was added to the medium perfusing the myocytes, the EPA was extracted from the myocy" @default.
• W2150541210 created "2016-06-24" @default.
• W2150541210 creator A5030599421 @default.
• W2150541210 creator A5063572740 @default.
• W2150541210 creator A5070369219 @default.
• W2150541210 creator A5079152086 @default.
• W2150541210 date "2003-06-03" @default.
• W2150541210 modified "2023-10-16" @default.
• W2150541210 title "Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils" @default.
• W2150541210 cites W1579904080 @default.
• W2150541210 cites W1935730507 @default.
• W2150541210 cites W1967182629 @default.
• W2150541210 cites W1973611043 @default.
• W2150541210 cites W1983531379 @default.
• W2150541210 cites W1983716025 @default.
• W2150541210 cites W1991732282 @default.
• W2150541210 cites W1994452561 @default.
• W2150541210 cites W1998430513 @default.
• W2150541210 cites W2001439169 @default.
• W2150541210 cites W2010224190 @default.
• W2150541210 cites W2014226775 @default.
• W2150541210 cites W2014800958 @default.
• W2150541210 cites W2030042443 @default.
• W2150541210 cites W2042309135 @default.
• W2150541210 cites W2056501002 @default.
• W2150541210 cites W2062414170 @default.
• W2150541210 cites W2080621715 @default.
• W2150541210 cites W2087878463 @default.
• W2150541210 cites W2088269052 @default.
• W2150541210 cites W2093707571 @default.
• W2150541210 cites W2124589611 @default.
• W2150541210 cites W2126403835 @default.
• W2150541210 cites W2128788220 @default.
• W2150541210 cites W2149342776 @default.
• W2150541210 cites W2166154572 @default.
• W2150541210 cites W2166326216 @default.
• W2150541210 cites W2192223169 @default.
• W2150541210 doi "https://doi.org/10.1161/01.cir.0000069566.78305.33" @default.
• W2150541210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12782616" @default.
• W2150541210 hasPublicationYear "2003" @default.
• W2150541210 type Work @default.
• W2150541210 sameAs 2150541210 @default.
• W2150541210 citedByCount "567" @default.
• W2150541210 countsByYear W21505412102012 @default.
• W2150541210 countsByYear W21505412102013 @default.
• W2150541210 countsByYear W21505412102014 @default.
• W2150541210 countsByYear W21505412102015 @default.
• W2150541210 countsByYear W21505412102016 @default.
• W2150541210 countsByYear W21505412102017 @default.
• W2150541210 countsByYear W21505412102018 @default.
• W2150541210 countsByYear W21505412102019 @default.
• W2150541210 countsByYear W21505412102020 @default.
• W2150541210 countsByYear W21505412102021 @default.
• W2150541210 countsByYear W21505412102022 @default.
• W2150541210 countsByYear W21505412102023 @default.
• W2150541210 crossrefType "journal-article" @default.
• W2150541210 hasAuthorship W2150541210A5030599421 @default.
• W2150541210 hasAuthorship W2150541210A5063572740 @default.
• W2150541210 hasAuthorship W2150541210A5070369219 @default.
• W2150541210 hasAuthorship W2150541210A5079152086 @default.
• W2150541210 hasBestOaLocation W21505412101 @default.
• W2150541210 hasConcept C111472728 @default.
• W2150541210 hasConcept C126322002 @default.
• W2150541210 hasConcept C138885662 @default.
• W2150541210 hasConcept C164705383 @default.
• W2150541210 hasConcept C185592680 @default.
• W2150541210 hasConcept C19038510 @default.
• W2150541210 hasConcept C2775935837 @default.
• W2150541210 hasConcept C2779946292 @default.
• W2150541210 hasConcept C2909208804 @default.
• W2150541210 hasConcept C2993353509 @default.
• W2150541210 hasConcept C505870484 @default.
• W2150541210 hasConcept C543025807 @default.
• W2150541210 hasConcept C55493867 @default.
• W2150541210 hasConcept C71924100 @default.
• W2150541210 hasConcept C86803240 @default.
• W2150541210 hasConcept C89611455 @default.
• W2150541210 hasConceptScore W2150541210C111472728 @default.
• W2150541210 hasConceptScore W2150541210C126322002 @default.
• W2150541210 hasConceptScore W2150541210C138885662 @default.
• W2150541210 hasConceptScore W2150541210C164705383 @default.
• W2150541210 hasConceptScore W2150541210C185592680 @default.
• W2150541210 hasConceptScore W2150541210C19038510 @default.
• W2150541210 hasConceptScore W2150541210C2775935837 @default.
• W2150541210 hasConceptScore W2150541210C2779946292 @default.
• W2150541210 hasConceptScore W2150541210C2909208804 @default.
• W2150541210 hasConceptScore W2150541210C2993353509 @default.
• W2150541210 hasConceptScore W2150541210C505870484 @default.
• W2150541210 hasConceptScore W2150541210C543025807 @default.
• W2150541210 hasConceptScore W2150541210C55493867 @default.
• W2150541210 hasConceptScore W2150541210C71924100 @default.
• W2150541210 hasConceptScore W2150541210C86803240 @default.
• W2150541210 hasConceptScore W2150541210C89611455 @default.
• W2150541210 hasIssue "21" @default.
• W2150541210 hasLocation W21505412101 @default.
• W2150541210 hasLocation W21505412102 @default.
• W2150541210 hasOpenAccess W2150541210 @default.
• W2150541210 hasPrimaryLocation W21505412101 @default.

• next